Lipid-core nanocapsules (LNCs) are core-shell structures, in which the core is an organogel formed by a solid lipid dispersed in a triglyceride, and the shell is a polymer. Those nanocapsules encapsulate poorly-water soluble drugs by dispersion in the core and/or interaction with the polymer. The core and the shell act as diffusional barriers differenting the LNC from previously developed polymeric nanocapsules containing an oily core and a polymer shell, which unique diffusional barrier is the shell. In this review, we discuss the supramolecular structure, the physico-chemical characterization, including sizing, surface potential, fluorescent labeling strategies, as well as the interfacial reactions in water to coat and functionalise the LNC surface. Different organometallic complexes have been synthesized to decorate the nanocapsules envisaging the treatment of atherosclerosis, cancer, mucopolysaccharidosis I, and hypertension. We also describe the main applications of the nanoformulations in the pharmaceutical, medical, and veterinary fields, including in vitro and in vivo evaluations of toxicity and efficacy. Lipidcore Lipid LNCs (LNCs coreshell structures triglyceride poorlywater poorly andor or review structure physicochemical physico chemical characterization sizing potential strategies atherosclerosis cancer I hypertension pharmaceutical medical fields efficacy

In this work we present a simple model for the kinetics of agglomeration and aggregation of colloidal particles. We consider that particles agglomerate rapidly and endothermically forming oligomers. These oligomers can, in turn, aggregate irreversibly, in a process that leads to the destabilization of the colloidal system. As these two processes have very different relative energy activations, they occur in different time-scales: the first step is faster and reaches a state of quasi‑equilibrium. Because of this, the enthalpy change during the agglomeration can be experimentally determined through the variable temperature multiple light scattering (VTMLS) method. Interestingly, this value is related to the relative kinetic stability of the system and can be used to evaluate the stability of new colloidal compositions. Our results are in qualitative agreement with experimental data of low concentration colloidal dispersions consisted of polymer particles and/or surfactant-coated particles.

In spite of different methods reported in the literature to determine olanzapine in biological fluids, all of them used high volumes of plasma. Therefore, the purpose of this paper was to develop an LC-MS/MS method using small plasma volume (0.1 mL) to apply in a preclinical pharmacokinetic investigation. The method was linear over the concentration ranges of 10 - 1000 ng mL-1. Extraction recoveries, stability, and validation parameters were evaluated. Results were within the acceptable limits of international guidelines. A significant decrease in clearance led to a significant 2.26-times increase in AUC0 - 6h of olanzapine-loaded lipid-core nanocapsules compared with free-olanzapine.

Several studies have described the benefits of nanoscience and nanotechnology (N&N) in different sectors such as agriculture, energy, environmental preservation, and public health. The rapid evolution of N&N can be shown through a panoramic analysis of scientific papers and patents. In the area of public health, it is estimated that the global market for nanotechnology products will expand to 160 billion U.S. dollars in 2015. The Brazilian government has also strengthened its innovative potential in N&N through economic subsidies, as observed for other countries. This review is focused on the current landscape of N&N in a therapeutic context, highlighting the development of nanotech-products produced with biocompatible and biodegradable materials that are already commercially available or under investigation. Most studies under investigation are focused on the development of nanotechnology-based formulations intended for treatment of cancer, inflammatory, cardiovascular, and neurological diseases. Although there are several advantages of N&N in healthcare, many challenges have to be conquered to increase the availability of nanotechnology products in toxicological, preclinical and clinical studies, scale-up, regulatory, and private investments.

Micropartículas de poli(3-hidroxibutirato-co-3-hidroxivalerato) (PHBV) contendo um fármaco modelo hidrofílico, o cloridrato de metformina (MH), foram obtidas pela técnica de emulsão múltipla/evaporação do solvente. Diversas formulações foram preparadas, com o objetivo de investigar a influência de cada composição sobre a eficiência de encapsulação (EE). O resultado mais elevado de EE (9,76%) foi verificado quando da simultânea alcalinização e adição de NaCl na fase aquosa externa da formulação. O estudo por MEV das micropartículas revelou morfologia esférica e superfície rugosa. As intensidades de difração cristalina para as micropartículas contendo o MH foram menores do que aquelas observadas para a mistura física. Os resultados obtidos por IVTF sugerem que nenhuma ligação química foi formada entre o polímero e o fármaco. A avaliação por análise térmica indica o surgimento de interações favoráveis entre MH e PHBV. O estudo de liberação in vitro demonstrou a influência do PHBV no perfil de dissolução do MH.

Poly(3-hydroxybutirate-co-3-hydroxyvalerate) (PHBV) microparticles containing a water-soluble model drug, metformin hydrochloride (MH), were obtained by a double emulsion/solvent evaporation technique. Several formulations were prepared in order to investigate the influence of each composition on the encapsulation efficiency (EE). The highest value of EE (9.76%) was obtained using simultaneously pH alkalinization and NaCl addition in the external water phase of the formulation. SEM study revealed a spherical morphology and a rough surface. The crystalline diffraction intensities for the MH-loaded microparticles were lower than that verified for the physical mixture. FTIR results suggested that no chemical bond between the polymer and the drug was formed. Also thermal analyses indicated a favorable interaction between MH and PHBV. In vitro drug release demonstrated the influence of the PHBV on the dissolution profile of MH.

Suspensões de nanocápsulas contendo melatonina foram preparadas pelo método de deposição interfacial e caracterizadas (tamanho, morfologia e eficiência de encapsulação). Foram avaliadas as influências do tipo de polímero, de óleo e de tensoativo sobre as características dos produtos. A eficiência de encapsulação da melatonina variou de 30% a 56% e a natureza do polímero foi o parâmetro de maior influência. De acordo com a maior eficiência de encapsulação, nanocápsulas preparadas com Eudragit S100® foram selecionadas para secagem por aspersão, objetivando-se aumentar a estabilidade física das suspensões e controlar a liberação da melatonina. O pó obtido apresentou eficiência de encapsulação de 93% e não sofreu nenhuma alteração morfológica após 12 meses de armazenamento. Este sistema apresentou perfil de liberação controlado, comparativamente ao fármaco puro, o qual foi ajustado ao modelo monoexponencial. O mecanismo de liberação da melatonina foi baseado em intumescimento e dissolução do polímero.

Nanocapsule suspensions containing melatonin were prepared by interfacial deposition method and characterized (size, morphological aspect and encapsulation efficiency). The formulation parameters studied were the oil nature, the type of surfactants and the type of polymer. The melatonin-encapsulation efficiency ranged between 30% and 56% and polymer nature was the parameter that more influenced the characteristics of suspensions. According to the highest encapsulation efficiency, the nanocapsules prepared with Eudragit S100® were selected to be spray-dried in order to improve the physical stability of suspension and to control the release of melatonin. The melatonin-loaded nanocapsule spray-dried powder presented encapsulation efficiency of the 93% and no morphological alterations were observed after 12 months of storage. This system showed a controlled release profile in comparison to the dissolution of the pure melatonin. The release profile was fitted to monoexponential model and the melatonin release mechanism was based on swelling and dissolution of the polymer.

Micropartículas com revestimento nanoestruturado, contendo diclofenaco, foram preparadas e caracterizadas apresentando um rendimento de 80% e taxa de encapsulação de 83%. A análise morfológica (MEV) permitiu a visualização de nanoestruturas adsorvidas à superfície das micropartículas, que apresentaram uma diminuição da área superficial e do volume de poros em relação ao núcleo. A liberação in vitro do fármaco (pH 5,0 e 7,4) mostrou eficiência de dissolução de 34% e 78% (núcleo), 74% e 83% (mistura física), e 58% e 85% (micropartículas nanorrevestidas), respectivamente. A modelagem matemática mostrou os modelos biexponencial (pH 5,0) e monoexponencial (pH 7,4) como aqueles que melhor descreveram os perfis de liberação. Na tolerância digestiva, os índices lesionais totais foram de 156,1 ± 48,5 para a solução do diclofenaco sódico, de 132,4 ± 45,7 para o núcleo, de 109,1 ± 35,8 para a mistura física e de 29,9 ± 12,1 para as micropartículas, demonstrando o efeito protetor destas micropartículas frente à toxicidade do diclofenaco. Esta estratégia de revestimento apresenta um emprego potencial no desenvolvimento de sistemas de administração oral de fármacos.

This work reports the preparation and characterization of polymeric nanostructure-coated diclofenac-loaded microparticles. After spray-drying, powders presented 80% of yield and encapsulation efficiency of 83%. SEM analyses showed nanostructures adsorbed onto the surface of microparticles presenting surface area (BET) and pore volumes (BJH) (83 m² g-1, 0.10 cm³ g-1) smaller than the uncoated-core (163 m² g-1, 0.25 cm³ g-1). In vitro drug release experiments at pH 5.0 and 7.4 showed dissolution efficiencies of 34% and 78% (uncoated-core), 74% and 83% (physical mixture of raw materials), and 58% and 85% (nanostructure-coated microparticles), respectively. Mathematical modeling of the dissolution profiles fitted a biexponential model at pH 5.0 and a monoexponential model at pH 7.4. Regarding the digestive tolerance experiments, the total lesional indexes were 156.1 ± 48.5 for sodium diclofenac aqueous solution, 132.4 ± 45.7 for uncoated-core, 109.1 ± 35.8 for physical mixture and 29.9 ± 12.1 for microparticles showing a protective effect of these microparticles against the mucosal diclofenac damage. This strategy of coating presents a potential use for oral administration of drugs.

A dessimetrização mais eficiente do composto meso-exo-3,5-dihidroximetilenotriciclo[5.2.1.0(2,6)]decano foi com a lipase da Pseudomonas cepacia (PS-C 'Amano' II) em acetato de vinila, quando obteve-se alto rendimento químico (93%) e excelente excesso enantiomérico (ee > 99%), determinado por cromatografia gasosa em coluna quiral. Desse sistema quiral, foram preparados derivados enantiopuros com potenciais aplicações como intermediários sintéticos.

meso-exo-3,5-dihydroxymethylenetricyclo[5.2.1.0(2,6)]decane was efficiently desymmetrized by the lipase from Pseudomonas cepacia (PS-C 'Amano' II) in vinyl acetate in high yields (93%) and with excellent enantiomeric excesses (ee > 99% by chiral GC). Chiral synthons for asymmetric synthesis were synthesized from this enantiopure compound.